Supplemental material
Modern Rheumatology
Volume 31, 2021 - Issue 3
Rheumatoid Arthritis
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years
Tsutomu Takeuchia Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0003-1111-8218View further author information
https://orcid.org/0000-0003-1111-8218View further author information, Yoshiya Tanakab The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japanhttps://orcid.org/0000-0002-0807-7139View further author information
https://orcid.org/0000-0002-0807-7139View further author information, Mitsuhiro Rokudac Astellas Pharma Inc., Tokyo, Japanhttps://orcid.org/0000-0001-5790-7146View further author information
https://orcid.org/0000-0001-5790-7146View further author information, Hiroyuki Izutsuc Astellas Pharma Inc., Tokyo, Japanhttps://orcid.org/0000-0002-2193-8327View further author information
https://orcid.org/0000-0002-2193-8327View further author information, , & Daisuke Katoc Astellas Pharma Inc., Tokyo, Japanhttps://orcid.org/0000-0003-1710-4319View further author information
https://orcid.org/0000-0003-1710-4319View further author information show all